Skip to main content
S&P 5007,711.06+1.88%DOW53,293.19+2.91%NASDAQ25,904.76+2.10%BTC$80,617.00+3.72%ETH$2,430.56+5.69%GOLD$4,076.60+3.46%OIL$88.12-8.29%
Smart Investors Daily
SID Premium
Biodexa Pharmaceuticals Plc logo

NASDAQ · BDRX

Biodexa Pharmaceuticals Plc

Healthcare · Biotechnology

$2.82

Down-$0.02 (-0.71%)

Updated Nov 4, 2026, 4:20 PM

SID Score

6.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
4.12M
P/E ratio
-0
Dividend yield
0.00%
52-week range
$0.34 – $8.94
Volume
9.23K
Avg. volume
695.79K

Price performance · BDRX

BDRX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

BDRX closed at $2.82 after 21 trading sessions, up 373.87% for the selected period.

Last close
$2.82
Period change
+373.87%
Period low
$0.35
Period high
$4.14
Daily close
View OHLC price history
BDRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$2.90$3.0301$2.75$2.829.23K
Nov 2, 2026$3.24$3.25$2.78$2.8018.98K
Oct 30, 2026$3.825$3.95$3.42$3.4329.38K
Oct 29, 2026$4.025$4.07$3.70$3.9044.78K
Oct 28, 2026$3.89$4.23$3.89$4.1460.24K
Oct 27, 2026$3.51$4.11$3.485$3.93117.62K
Oct 26, 2026$3.30$3.8254$3.185$3.6941.96K
Oct 23, 2026$3.076$3.44$3.076$3.386430.08K
Oct 22, 2026$3.1992$3.32$3.128$3.31212.05K
Oct 21, 2026$3.1928$3.4948$3.06$3.359231.67K
Oct 20, 2026$2.992$3.212$2.9768$3.084420.35K
Oct 19, 2026$0.4304$0.4304$0.3743$0.3906575.05K
Oct 16, 2026$0.446$0.47$0.4401$0.4561631.11K
Oct 15, 2026$0.47$0.5118$0.41$0.43142.99M
Oct 14, 2026$0.4978$0.54$0.4039$0.484953.25M
Oct 13, 2026$0.4169$0.42$0.3371$0.350222.98M
Oct 12, 2026$0.47$0.47$0.378$0.3832266.6K
Oct 9, 2026$0.52$0.52$0.45$0.4602157.84K
Oct 8, 2026$0.55$0.55$0.5108$0.5237113.43K
Oct 7, 2026$0.571$0.59$0.53$0.5638149.66K
Oct 6, 2026$0.6223$0.636$0.594$0.5951273.79K

Latest BDRX news

The latest Smart Investors Daily articles mentioning BDRX.

Stock researchCompany · Overview

BDRX research

Overview

Company profile and research snapshot.

Company profile

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$183.60
Implied upside
—
Analysts
7
BDRX recent ratings
DateFirmRatingTarget
Feb 8, 2024Ladenburg ThalmannBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 13, 2026

Biodexa Reaches 100-Patient Enrollment Milestone in Phase 3 Serenta Trial as Key Analysis Timeline Accelerates

Biodexa Pharmaceuticals (NASDAQ:BDRX) has enrolled 100 patients in its registrational Phase 3 Serenta trial of eRapa for Familial Adenomatous Polyposis, with an interim futility analysis and database lock now potentially occurring earlier than originally anticipated. Key Investor TakeawaysBiodexa (NASDAQ:BDRX) has enrolled 100 of the planned 168 patients in its Phase 3 Serenta trial, representing approximately 60% of its recruitment target.

Yahoo · Oct 13, 2026

Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP

October 13, 2026 Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP Update on expected timing of pre-specified futility analysis and database lock Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has enrolled 100 patients in its registration

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By